A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin).
Indian J Ophthalmol
;
2007 Nov-Dec; 55(6): 437-9
Article
in English
| IMSEAR
| ID: sea-69682
ABSTRACT
Wet age-related macular degeneration and diabetic retinopathy are pathological consequences of vascular endothelial growth factor (VEGF) release as a reaction to deficiency of oxygen and nutrients in the macular cells. Conventional treatment modalities have been constrained by limited success. Convincing evidence exists that targeting VEGF signaling is a significant approach for the therapy of these ocular angiogenesis-dependent disorders. We have come a long way since the approval of the first angiogenesis inhibitors in medicine. The clinical use of these drugs has provided enormous tempo to clinical and pharmacological research. It has also significantly altered patient outcome and expectations. In the following brief, we will discuss the development and emergence of these drugs as well as the anticipated future course based on evidence.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Humans
/
Treatment Outcome
/
Angiogenesis Inhibitors
/
Vascular Endothelial Growth Factor A
/
Diabetic Retinopathy
/
Aptamers, Nucleotide
/
Macular Degeneration
/
Antibodies, Monoclonal
Language:
English
Journal:
Indian J Ophthalmol
Year:
2007
Type:
Article
Similar
MEDLINE
...
LILACS
LIS